Herriot Tabuteau: Sure, Graig. So the growth to net for Auvelity in the quarter was approximately 50%. That was an improvement from the previous quarter, which had a GTN discount that was in the low to mid-50s. Sunosi as well was in that low 50s, very similar to where we saw in the previous quarter. As it relates to inventory, we’ve always shared that. We maintain roughly two weeks of inventory in channels. So there was no inflection as it relates to the sales for inventory for neither Auvelity nor Sunosi.
Graig Suvannavejh: Right, thanks. And then — Sunosi — it’s actually there, you’ve done a nice product, but given peak sales that you’ve put out there of 300 million to 500 million. I’m just wondering if maybe you can comment on kind of how we should expect kind of the time to peak sales and what the dynamic might look like between OSA and narcolepsy. Thanks.
Lori Englebert: Yeah, Graig, I’ll answer and then Nick feel free to chime in if there’s anything else you want to add. So right now the split between OSA and narcolepsy is about 70% OSA, 30% narcolepsy. That’s to be expected. OSA prevalence is about 22 million patients, whereas narcolepsy is 185,000 to 200,000. So we do expect OSA to continue to increase. Right now, of those 22 million OSA patients, only about a million patients are actually drug treated. So, our path to peak sales will come with increased efforts in education and understanding of OSA and treating the disease, which we are very heavily doing and have started doing several quarters ago. So we are anticipating that promotional effort will continue and peak sales will soon follow.
Nick Pizzie: Yeah and the other thing maybe I’ll add is that while we’re continuing to grow very nicely in the US market, ex-US, there’s been a refocus with the Pharmanovia transaction that was announced earlier. And Pharmanovia is really ramping up their sales and marketing strategy. And we would expect to start seeing significant international sales and from our perspective, royalty revenue as it relates to the Pharmanovia strategy.
Graig Suvannavejh: Okay, thank you.
Operator: Thank you. The next question is coming from Myles Minter of William Blair. Please go ahead.
Unidentified Analyst: Hi. Good morning. You’ve got Sarah on for Myles. Congrats on another great quarter. So two quick ones from us. Do you guys have any internal goals about the Auvelity prescribing mix between primary care physicians and specialty referral accounts? And then secondly, is there any read-through or learning from the Rexulti approval in Alzheimer’s disease agitation and how do you see AXS-05 differentiating from that recently approved option? Thanks.
Lori Englebert: Hey, Sarah. I’ll take the first one. So in terms of, you know, goals, we don’t really — we don’t typically look at it that way. As mentioned, we take a look at the prescribers that are most likely to prescribe. Right now, there’s about 80% psych, 20% PCP. That’s to be expected, especially with a novel mechanism of action and a new product coming to market. Consistent with our expansion and as we expand out to broader PCP sets, we do expect that to level out a little bit.
Herriot Tabuteau: Great. And with regards to Rexulti and any learnings from there, we’ve been happy with our clinical development plan with regards to AXS-05 and Alzheimer’s disease agitation. We like the clinical profile thus far from our completed trials, which have been consistent. And we think that it is and will remain differentiated as it relates to Rexulti.
Unidentified Analyst: Great. Thanks for taking the question.
Operator: Thank you. We’re showing time for one final question today. The last question is coming from Matt Kaplan of Ladenburg Thalmann. Please go ahead.
Matt Kaplan: Hey, good morning, guys, and thanks for taking the question, and congrats on the strong quarter. Just wanted to talk a little bit about the ADHD opportunity for Sunosi and what the potential is there and can describe the market maybe more for Lori in terms of the unmet need there.
Lori Englebert: Yeah. Hey, Matt. Yeah, we, again, we are very excited about ADHD for solriamfetol. Prevalence for ADHD across, you know, pediatrics as well as adults and adolescents is about 17 million, so highly prevalent condition. It’s a very large market right now lots of prescriptions on a monthly basis. The way that you can take a look at the market and think about the market now and the way that we’re evaluating is really break it up into stimulants and non-stimulants. Stimulants really have rather large effect sizes, but they do have safety risks that come along with that while your non-stimulants are safer, but they have less effect sizes. So we are excited again for the opportunity for solriamfetol and ADHD.
Matt Kaplan: Thanks again.
Operator: Thank you. At this time, I’d like to turn the call back over to Axsome CEO for any concluding remarks.
Herriot Tabuteau: Well, we thank you all for joining us on today’s call. I am proud of the efforts made by our outstanding team at Axsome. We’re excited by the opportunity ahead of us for both Sunosi and Auvelity as we continue to progress our industry-leading CNS pipeline. As we close out 2023, we are on track to deliver on multiple potentially value-driving milestones on the clinical and regulatory fronts over the next 12 months. Our team is working hard to deliver on our goal of having potentially at least five marketed products by 2025. We look forward to updating you on our progress. Have a great rest of your day.
Operator: Ladies and gentlemen, thank you for your participation. This concludes today’s event. You may disconnect your lines and log off the webcast at this time. And enjoy the rest of your day.
